Jubilant Ingrevia Limited (JUBLINGREA.NS)
INR 800.95
(-4.21%)
INR 800.95
(-4.21%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 7.4 Billion INR | 81.99% |
| 2022 | 4.06 Billion INR | 71.02% |
| 2021 | 2.37 Billion INR | -57.2% |
| 2020 | 5.55 Billion INR | 0.0% |
| 2019 | - INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 7.12 Billion INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 FY | 7.4 Billion INR | 81.99% |
| 2023 Q4 | 7.4 Billion INR | 0.0% |
| 2023 Q2 | 7.65 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q2 | 3.93 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 4.06 Billion INR | 71.02% |
| 2022 Q4 | 4.06 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 2.37 Billion INR | -57.2% |
| 2021 Q4 | 2.37 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 2.73 Billion INR | 0.0% |
| 2020 FY | 5.55 Billion INR | 0.0% |
| 2020 Q4 | 5.55 Billion INR | 0.0% |
| 2020 Q3 | - INR | 0.0% |
| 2019 FY | - INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Biocon Limited | 162.76 Billion INR | 95.452% |
| Blue Jet Healthcare Limited | 16.12 Million INR | -45792.749% |
| Concord Biotech Limited | 97.37 Million INR | -7501.976% |
| Dishman Carbogen Amcis Limited | 23.12 Billion INR | 67.991% |
| Lyka Labs Limited | 586.5 Million INR | -1162.146% |
| Panacea Biotec Limited | 209.9 Million INR | -3426.679% |
| Piramal Pharma Limited | 47.1 Billion INR | 84.284% |
| SMS Lifesciences India Limited | 1 Billion INR | -634.931% |
| Supriya Lifescience Limited | 54.88 Million INR | -13388.52% |
| Syngene International Limited | 5.55 Billion INR | -33.33% |
| TAKE Solutions Limited | 370.85 Million INR | -1896.09% |
| Zota Health Care Limited | 952.84 Million INR | -676.883% |